Currently, there are 390.76M common shares owned by the public and among those 323.88M shares have been available to trade.
The company’s stock has a 5-day price change of -6.05% and 2.19% over the past three months. RXRX shares are trading -29.11% year to date (YTD), with the 12-month market performance down to -28.96% lower. It has a 12-month low price of $5.60 and touched a high of $15.74 over the same period. RXRX has an average intraday trading volume of 9.04 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.68%, 3.27%, and -9.92% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares accounts for 57.84% of the company’s 390.76M shares outstanding.
It has a market capitalization of $2.70B and a beta (3y monthly) value of 0.88. The earnings-per-share (ttm) stands at -$1.53. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.69% over the week and 10.39% over the month.
Earnings per share for the fiscal year are expected to increase by 2.45%, and -7.62% over the next financial year. EPS should grow at an annualized rate of 12.00% over the next five years, compared to -43.41% over the past 5-year period.
Looking at the support for the RXRX, a number of firms have released research notes about the stock. Morgan Stanley stated their Equal-Weight rating for the stock in a research note on May 22, 2023, with the firm’s price target at $8. Needham coverage for the Recursion Pharmaceuticals Inc (RXRX) stock in a research note released on March 16, 2023 offered a Buy rating with a price target of $17. KeyBanc Capital Markets was of a view on September 16, 2022 that the stock is Overweight, while BofA Securities gave the stock Neutral rating on April 18, 2022, issuing a price target of $10. SVB Leerink on their part issued Mkt Perform rating on March 04, 2022.
